ID: h-2d5e4bc423
Hypothesis
HBOT at 2.0 ATA for 60 minutes restores PGC-1α-mediated mitochondrial biogenesis, rescuing neuronal bioenergetics in AD
HBOT activates PGC-1α through AMPK and SIRT1 pathways, reducing hypoxia-induced mitochondrial fragmentation and restoring ATP production.
EvidencePending (0%)📖 0 cit🗣 1 debates✓ 3 support✗ 2 oppose
✓ All Quality Gates Passed
🧪 Overview
HBOT activates PGC-1α through AMPK and SIRT1 pathways, reducing hypoxia-induced mitochondrial fragmentation and restoring ATP production. However, mitochondrial biogenesis markers often rise as compensatory stress responses without net functional rescue. PGC-1α activation alone may be insufficient given the entanglement of mitochondrial dysfunction with proteostasis failure and calcium dysregulation in AD.
🧬 Mechanism
🧬 Curated Mechanism Pathway
Curated pathway from expert analysis
flowchart TD
A["AMPK / SIRT1 Activation<br/>Energy Deficit Signal"]
B["PGC-1alpha Deacetylation<br/>Transcriptional Co-activator"]
C["TFAM Induction<br/>Mitochondrial DNA Transcription"]
D["Mitochondrial Biogenesis<br/>New Organelle Formation"]
E["OXPHOS Complex I-V<br/>ATP Synthesis Enhanced"]
F["ROS Scavenging<br/>SOD2/GPX Upregulation"]
G["PGC-1alpha Reduced in AD/PD<br/>Metabolic Failure"]
H["Mitochondrial Dysfunction<br/>Synaptic Energy Deficits"]
A --> B
B --> C
B --> F
C --> D
D --> E
G -.->|"reduces"| B
G --> H
style A fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
style E fill:#1b5e20,stroke:#81c784,color:#81c784
style G fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
style H fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a⚖️ Evidence
⚖️ Evidence Matrix3 supports2 contradicts
Supports
HBOT improved mitochondrial membrane potential by 45% in neurons exposed to hypoxia
Contradicts
Mitochondrial biogenesis markers often rise as compensatory stress response without net functional rescue
Contradicts
More oxygen can increase mitochondrial ROS, especially in damaged AD mitochondria
📖 Linked Papers
No linked papers recorded for this hypothesis yet.
🏥 Translation
🧬 3D Protein Structure — PPARGC1A
No curated PDB or AlphaFold mapping for PPARGC1A yet. Search RCSB →
🧠 GTEx v10 Brain ExpressionJSON
Median TPM across 13 brain regions for PPARGC1A (PGC-1α) from GTEx v10.
💉 Clinical Trials
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for PPARGC1A (PGC-1α).
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
💰 Estimated Development
Cost
$0
Timeline
—
🏆 Tournament
🏆 Arenas / Elo
No arena matches recorded yet. Browse Arenas →
📊 Market Indicators
7d Trend
↔
Stable
7d Momentum
▲ 0.0%
Volatility
Low
0.0117
Events (7d)
0
Price History
▼0.1%💾 Resource Usage
LLM Tokens
11,804
$0.0354
Total Cost
$0.0354
🔮 Predictions
🔎 Predictions vs Observations2 predictions · 0 with recorded observations
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF patients with mild-to-moderate Alzheimer's Disease receive HBOT at 2.0 ATA for 60 minutes per session, 5 sessions weekly for 8 weeks, THEN cortical PGC-1α protein expression will increase by ≥50% A | PGC-1α protein levels measured by Western blot or ELISA in prefrontal cortex biopsy or PET radioligand binding will increase ≥50%; hippocampal ATP measured by 3 | — no observation — | pending | 0.45 |
| IF AD patients receive HBOT at 2.0 ATA for 60 minutes per session, 5 sessions weekly for 12 weeks AND demonstrate ≥40% increase in peripheral blood mononuclear cell (PBMC) PGC-1α mRNA and mitochondria | ADAS-Cog11 score change <3 points; no significant improvement in CSF Aβ42/40 ratio (change <10%) or CSF p-tau181 (change <15%); indicating that isolated PGC-1α- | — no observation — | pending | 0.38 |
🔮 Falsifiable Predictions (2)
pendingconf 45%
IF patients with mild-to-moderate Alzheimer's Disease receive HBOT at 2.0 ATA for 60 minutes per session, 5 sessions weekly for 8 weeks, THEN cortical PGC-1α protein expression will increase by ≥50% AND hippocampal ATP production will increase by ≥20% relative to sham-treated controls within 2 weeks
Predicted outcome: PGC-1α protein levels measured by Western blot or ELISA in prefrontal cortex biopsy or PET radioligand binding will increase ≥50%; hippocampal ATP mea
Falsification: PGC-1α expression increases ≥50% but ATP production does not increase ≥20%, indicating uncoupling between PGC-1α activation and functional mitochondrial rescue; or neither marker changes significantly
pendingconf 38%
IF AD patients receive HBOT at 2.0 ATA for 60 minutes per session, 5 sessions weekly for 12 weeks AND demonstrate ≥40% increase in peripheral blood mononuclear cell (PBMC) PGC-1α mRNA and mitochondrial DNA copy number as proxy for systemic mitochondrial biogenesis, THEN global cognitive function wil
Predicted outcome: ADAS-Cog11 score change <3 points; no significant improvement in CSF Aβ42/40 ratio (change <10%) or CSF p-tau181 (change <15%); indicating that isolat
Falsification: Significant cognitive improvement (ADAS-Cog11 decrease ≥4 points) OR normalization of CSF Aβ42/40 ratio (increase ≥15%) AND CSF p-tau181 decrease ≥20% despite PGC-1α activation, disproving the claim t
▸Metadatasource: v1_phase_c_backfill · origin_type: debate_synthesizer
| source | v1_phase_c_backfill |
| origin_type | debate_synthesizer |
| _schema_version | 1 |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.